Is MAXCYTE, INC. (MXCT) Halal?

NASDAQ Healthcare United States $73M
✗ NOT HALAL
Confidence: 90/100
MAXCYTE, INC. (MXCT) is Not Halal under AAOIFI Standard 21. While the debt ratio of 21.6% is acceptable, the cash and interest-bearing securities ratio of 185.1% exceeds the 30% threshold. MAXCYTE, INC. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 21.6%
/ 30%
185.1%
/ 30%
5.6%
/ 30%
26.26%
/ 5%
✗ NOT HALAL
DJIM 21.6%
/ 33%
185.1%
/ 33%
5.6%
/ 33%
26.26%
/ 5%
✗ NOT HALAL
MSCI 7.5%
/ 33%
64.5%
/ 33%
2.0%
/ 33%
26.26%
/ 5%
✗ NOT HALAL
S&P 21.6%
/ 33%
185.1%
/ 33%
5.6%
/ 33%
26.26%
/ 5%
✗ NOT HALAL
FTSE 7.5%
/ 33%
64.5%
/ 33%
2.0%
/ 50%
26.26%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-0.42
P/B Ratio
0.4
EV/EBITDA
0.3
EV: -$12M
Revenue
$39M
Growth: -16.0%
Beta
1.4
High volatility
Current Ratio
8.3

Profitability

Gross Margin 81.2%
Operating Margin -94.8%
Net Margin -135.1%
Return on Equity (ROE) -23.6%
Return on Assets (ROA) -12.6%

Cash Flow & Balance Sheet

Operating Cash Flow-$28M
Free Cash Flow-$29M
Total Debt$18M
Debt-to-Equity10.5
Current Ratio8.3
Total Assets$239M

Price & Trading

Last Close$0.72
50-Day MA$0.85
200-Day MA$1.49
Avg Volume1.1M
Beta1.4
52-Week Range
$0.64
$2.96

About MAXCYTE, INC. (MXCT)

CEO
Mr. Maher Masoud
Employees
91
Sector
Healthcare
Industry
Medical Devices
Country
United States
Exchange
NASDAQ
Market Cap
$73M
Currency
USD

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is MAXCYTE, INC. (MXCT) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), MAXCYTE, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is MAXCYTE, INC.'s debt ratio?

MAXCYTE, INC.'s debt ratio is 21.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.5%.

What are MAXCYTE, INC.'s key financial metrics?

MAXCYTE, INC. has a market capitalization of $73M, and revenue of $39M. The company maintains a gross margin of 81.2% and a net margin of -135.1%. Return on equity stands at -23.6%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.